Pipeline


Robust pipeline in severe autoimmune diseases with potential to address a wide range of diseases

Imcyse is initially applying its ImotopeTM technology for the treatment of severe, chronic autoimmune diseases where no therapeutic cures are available and existing therapies manage disease symptoms often with frequent and severe side effects. However, the ImotopeTM platform is highly adaptable and can be modified for use in a variety of diseases beyond autoimmune diseases.

The Company’s robust pipeline currently comprises clinical-stage programs in Type 1 diabetes and Multiple sclerosis as well as pre-clinical programs in Neuromyelitis optica, Celiac disease and Rheumatoid arthritis.

Other early-stage, pre-clinical programs include proof-of-concept studies in allergies, graft vs. host rejection, and Myasthenia gravis, as well as in the prevention of immunogenicity in gene therapies using AAV vectors. The ImotopeTM platform also has the potential to address a wide range of immunologic diseases.

  • IMOTOPE™ DESIGN
  • LEAD SELECTION
  • PRECLINICAL
  • Ph1

  • Ph2


Jean Van Rampelbergh

Ph.D, Chief Clinical Development Officer

©imcyse 2023